Sulfinpyrazone

MUSCULO-SKELETAL SYSTEM

Key facts

Sulfinpyrazone is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1959. DrugCentral lists 4 molecular targets, including NAPRT, FPR1 and SLC22A12. Recorded indications include Chronic gouty arthritis and Hyperuricemia.

• Approval status: ofm (first approved 1959 by the FDA).
• Molecular targets: NAPRT, FPR1, SLC22A12 and ABCC1 (4 listed in DrugCentral).
• Indications: Chronic gouty arthritis and Hyperuricemia.
• ATC code: M04AB02 (Preparations increasing uric acid excretion).
• Molecular formula: C23H20N2O3S; molecular weight 404.48 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Chronic gouty arthritis
• Hyperuricemia

Contraindications (9)

• Acute peptic ulcer
• Chronic peptic ulcer
• Dehydration
• Disease of blood AND/OR blood-forming organ
• Gastrointestinal ulcer
• Inflammatory bowel disease
• Kidney disease
• Renal colic
• Urolithiasis

Mechanism & targets

Molecular targets (4)

Target	Gene	Action	Activity
Nicotinate phosphoribosyltransferase	NAPRT	unknown	Ki 9.30
fMet-Leu-Phe receptor	FPR1	unknown	Ki 4.70
Solute carrier family 22 member 12	SLC22A12	inhibitor	IC50 4.00
Multidrug resistance-associated protein 1	ABCC1	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1959-05-13	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
M04AB02	MUSCULO-SKELETAL SYSTEM › ANTIGOUT PREPARATIONS › ANTIGOUT PREPARATIONS › Preparations increasing uric acid excretion

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Sulfinpyrazone is on its molecule page.

• Molecular formula: C₂₃H₂₀N₂O₃S
• Molecular weight: 404.48 g/mol
• CAS number: 57-96-5
• InChIKey: MBGGBVCUIVRRBF-UHFFFAOYSA-N
• PubChem CID: 5342

O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sulfinpyrazone used for?

DrugCentral lists the following indications for Sulfinpyrazone: Chronic gouty arthritis and Hyperuricemia.

How does Sulfinpyrazone work?

Its molecular targets in DrugCentral include NAPRT, FPR1, SLC22A12 (inhibitor) and ABCC1.

When was Sulfinpyrazone first approved?

Sulfinpyrazone was first approved by the FDA in 1959.

What is the chemical formula of Sulfinpyrazone?

Sulfinpyrazone has the molecular formula C23H20N2O3S and a molecular weight of 404.48 g/mol.

Sources

• DrugCentral drug card 2528 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL832 — compound record and bioactivity
• PubChem CID 5342 — chemical identifiers
• DrugBank DB01138 — drug record
• FDA UNII V6OFU47K3W — substance identity
• DailyMed: FDA labels for Sulfinpyrazone — current prescribing information (label search)
• UniProt Q6XQN6 (NAPRT) — target protein
• UniProt P21462 (FPR1) — target protein
• UniProt Q96S37 (SLC22A12) — target protein
• UniProt P33527 (ABCC1) — target protein

How this page is built: methodology · editorial policy & corrections.